This Foley Executive Briefing Series program examined the common sources of litigation for life sciences companies as well as methods for mitigating exposure when these issues arise.
The program explored the potential litigation challenges that arise in light of intellectual property (IP) issues, IP ownership challenges arising out of collaborations or movements of personnel, and conflicts of interest in research, and addressed their implications for life sciences companies.
Questions that were discussed include:
- What are the key exposure areas for life sciences companies?
- What is involved in litigating these issues?
- What types of relief may be sought?
- What does litigation cost?
- Are there alternatives to litigation?
This interactive program was moderated by Foley Partners J. Mark Waxman and Thomas I. Elkind.
People
Related Insights
July 2, 2025
Energy Current
Has SCOTUS Pre-decided Whether the NRC Can License Private Off-Site High-Level Nuclear Waste Storage Facilities?
On June 18, 2025, the U.S. Supreme Court, in NRC v. Texas, issued an opinion holding that the State of Texas did not have standing to…
July 2, 2025
Health Care Law Today
AI-Powered Text Messaging by Digital Health Companies: Supreme Court Raises the Stakes
Digital health companies increasingly rely on AI-powered messaging platforms, chatbots, and virtual assistants to engage patients through…
July 2, 2025
Innovative Technology Insights
AI-Powered Text Messaging by Digital Health Companies: Supreme Court Raises the Stakes
Digital health companies increasingly rely on AI-powered messaging platforms, chatbots, and virtual assistants to engage patients through…